How it works, simply
It mimics GLP-1, a signal that helps regulate blood sugar and appetite.
What the evidence tells us
The approved uses differ between Ozempic, Wegovy and Rybelsus; their formulations are not interchangeable.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Nausea, vomiting and other gastrointestinal effects can occur.
- The label has a thyroid C-cell tumor boxed warning and specific contraindications; the human tumor risk is uncertain.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates the GLP-1 receptor to influence glucose-dependent insulin secretion, appetite and gastric emptying.
Sponsor or developer: Novo Nordisk
Studied or labeled topics: Type 2 diabetes, Chronic weight management, Cardiovascular risk reduction
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: WEGOVY prescribing information ↗ · Regulator · Jun 30, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.